Abstract
Preeclampsia remains a significant complication of pregnancy which emerges after the 20th week mark and is identified by proteinuria and hypertension. This review explores the multifaceted nature of preeclampsia, beginning with its complex pathology involving endothelial, platelet dysfunction and the imbalance in the factors that regulate angiogenesis. Diagnosis relies on monitoring blood pressure and assessing proteinuria, supported by laboratory tests and imaging studies to detect organ involvement. Biomarkers including Soluble fms-like tyrosine kinase (sFlt-1) and placental growth factor (PlGF) play a critical role in early detection and risk stratification. The imbalance in the ratio between these two biomarkers serves as a key in diagnosing and predicting preeclampsia. Vascular homeostasis is upset by this imbalance, which results in clinical symptoms such as hypertension and urinary protein excretion. Elevated sFlt-1 and reduced PlGF in high risk pregnancies, including those with chronic hypertension, correlate with greater clinical severity and predict adverse outcomes for maternal and fetal health. Management strategies include the use of antihypertensive medicines, fetal monitoring and delivery of the fetus based on disease severity. Despite ongoing research into predictive biomarkers and preventative measures, preeclampsia remains a challenge and necessitates a multidisciplinary approach for the well-being of both the fetus and the mother. This review serves as a comprehensive resource for clinicians and healthcare workers and by consolidating current knowledge and practical approaches allows them to stay updated on the evolving role of biomarkers in improving diagnostic accuracy.